Concepedia

Cytomegalovirus Prevention in High-risk Lung Transplant Recipients: Comparison of 3- vs 12-Month Valganciclovir Therapy

Péter Jaksch, B. Zweytick, Heidrun Kerschner, Ali Mir Hoda, M. Keplinger, György Láng, Clemens Aigner, Walter Klepetko

The Journal of Heart and Lung Transplantation · 2009 · 67 citations · 34 references

DOI

Concepts

References

34

Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation

David C. Lowance, Hans‐H. Neumayer, Christophe Legendre et al. · New England Journal of Medicine · 1999 · 716 citations · Full text

, , +17

Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients

Mark D. Pescovitz, John M. Rabkin, Robert M. Merion et al. · Antimicrobial Agents and Chemotherapy · 2000 · 363 citations

, , +15

Analysis of Risk Factors for the Development of Bronchiolitis Obliterans Syndrome

Aliya N. Husain, Momin T. Siddiqui, E W Holmes et al. · American Journal of Respiratory and Critical Care Medicine · 1999 · 268 citations

, , +14

Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation

Timothy J. Kroshus, Vibhu R. Kshettry, Kay Savik et al. · Journal of Thoracic and Cardiovascular Surgery · 1997 · 258 citations · Full text

, , +16

High Incidence of Ganciclovir‐Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy

Ajit P. Limaye, Ganesh Raghu, David M. Koelle et al. · The Journal of Infectious Diseases · 2002 · 225 citations · Full text

, , +16